ALMOF Stock Analysis
AL
Uncovered
Alphamab Oncology is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 493 full-time employees. The company went IPO on 2019-12-12. The firm is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The firm has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The firm operates its businesses in both domestic and overseas markets.